Sparks - Immix Biopharma

Immix Biopharma has announced the accelerated progress of the NEXICART-2 trial, which now has 18 active clinical trial sites (compared to 14 in the prior update, in May 2025). The NEXICART-2 trial is a US-based, open-label, single-arm, multi-site, dose-escalation/expansion Phase I/II trial. It is evaluating lead CAR-T therapy, NXC-201, as a potential treatment for patients with relapsed/refractory amyloid light chain amyloidosis (r/r ALA). Management has communicated that it is on track to submit a biologics license application once 40 r/r ALA patients have been treated (guided for mid-2026).

The latest clinical data readout was presented at ASCO 2025, corresponding to the first 10 patients treated in the trial. A complete response rate of 70% was reported, which was considered favourable, according to key opinion leaders (KOLs) in the corresponding KOL event.